Free Trial
LON:ONC

Oncimmune 2/10/2025 Earnings Report

Oncimmune EPS Results

Actual EPS
-GBX 4.72
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Oncimmune Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Oncimmune Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Oncimmune Earnings Headlines

New Federal Land Rush About to Start?
A $100 Trillion Wealth Shift Is Already Underway Lithium. Oil. Gold. Trillions in U.S. resources are being quietly opened to the public, and former hedge fund firm manager Whitney Tilson believes this is the best chance in years to turn a small stake into huge gains. He's naming one $10 stock leading this "US: IPO" boom.
Oncimmune Share Chat (ONC)
See More Oncimmune Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Oncimmune? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oncimmune and other key companies, straight to your email.

About Oncimmune

Oncimmune (LON:ONC), an immunodiagnostics company, develops solutions for immuno-oncology, autoimmune disease and infectious diseases in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, an immunodiagnostic blood test for detecting and identifying lung cancer; ImmunoINSIGHTS that enables life science organizations to optimize drug development and delivery; SeroTag discovery arrays for discovering and validating biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel. Oncimmune Holdings plc was incorporated in 2015 and is based in Leeds, the United Kingdom.

View Oncimmune Profile

More Earnings Resources from MarketBeat